Insomnia Market Growth Trajectory Through 2024-2033

Spread the love

The Insomnia Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Insomnia Market:

https://www.thebusinessresearchcompany.com/report/insomnia-global-market-report

According to The Business Research Company’s Insomnia Global Market Report 2024, The insomnia market size has grown strongly in recent years. It will grow from $4.72 billion in 2023 to $4.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increased stress levels, prevalence of mental health conditions, shift work and irregular work hours, increased awareness and diagnosis, high consumption of stimulants.

The insomnia market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to global health crisis impact, increasing awareness of sleep hygiene, emphasis on mental health and wellness, government initiatives for sleep health, influence of social determinants. Major trends in the forecast period include digital health solutions for sleep monitoring, cognitive behavioral therapy for insomnia , telehealth for sleep consultations, integration of sleep health into primary care, research on novel therapeutic targets.

The surge in work-related Stress is expected to propel the growth of the insomnia market going forward. Work-related Stress refers to harmful emotional and physical responses that occur when the work demands, and pressures do not match the worker’s resources, capabilities, or knowledge. Job stress can lead to poor health, including insomnia. Depending on the severity of insomnia, the patients are treated with drug or cognitive-behavioral therapies, among others. Thus, the surge in work-related Stress is boosting sales in the insomnia market. For instance, in October 2021, according to a survey of 1,500 US employees conducted by the American Psychology Association, a US-based professional organization of psychologists, approximately 59% of the respondents were experiencing work-related stress in 2021. Furthermore, in November 2022, according to the US Bureau of Labor Statistics, a US-based principal fact-finding agency of the US government, the total rate of injuries increased in 2021 to 2.3 cases per 100 full-time equivalent workers, up from 2.2 cases in 2020. Real-reported injuries in 2021 increased by 6.3% (2.2 million cases) compared to 2020 (2.1 million cases). Therefore, the surge in work-related Stress is driving the growth of the insomnia market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12120&type=smp

The insomnia market covered in this report is segmented –

1) By Therapy Type: Non-Pharmacological Therapy, Pharmacological Therapy

2) By Drug Class: Anti-Depressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, Other Drug Classes

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Product innovation is the key trend gaining popularity in the insomnia market. Major companies operating in the insomnia therapeutics market are developing innovative treatments to sustain their position in the market. For instance, in April 2023, WELT, a Korea-based medical device company, received approval from the Ministry of Food and Drug Safety (MFDS) for its digital insomnia treatment device, WELT-I. WELT-I was designated as an innovative medical aimed at correcting behavioral, psychological, and cognitive factors that sustain or worsen insomnia. The device delivers treatment based on cognitive behavioral therapy (CBT) as a first-line treatment in clinical guidelines for insomnia. The device is classified as a software as a medical device (SaMD), improving insomnia by performing personalized sleep time, analyzing sleep disturbance habits, intervening in patient behavior to enhance sleep quality, and delivering relaxation therapy for eight weeks to reduce tension and anxiety.

The insomnia market report table of contents includes: